Want to see NMRA full AI Analyst Report?
NMRA Stock Chart & Stats
$2.15
-$0.22(-8.53%)
At close: 4:00 PM EST
$2.15
-$0.22(-8.53%)
Day’s Range― - ―
52-Week Range$0.83 - $3.65
Previous CloseN/A
Volume2.95M
Average Volume (3M)490.26K
Market Cap
$294.60M
Enterprise Value$136.82M
Total Cash (Recent Filing)$147.07M
Total Debt (Recent Filing)$410.00K
Price to Earnings (P/E)―
Beta2.22
Next Earnings
Aug 12, 2026EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.33
Shares Outstanding185,284,240
10 Day Avg. Volume506,087
30 Day Avg. Volume490,256
Financial Highlights & Ratios
PEG Ratio0.24
Price to Book (P/B)2.82
Price to Sales (P/S)0.00
P/FCF Ratio-1.42
Enterprise Value/Market Cap0.46
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-27.32
Enterprise Value/Ebitda-0.63
Forecast
1Y Price Target
$6.67Price Target Upside210.08% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
EPS Forecast (FY)-0.91
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageVery low debt reduces bankruptcy and interest-rate risk, preserving strategic optionality for R&D and partnering decisions. Over 2–6 months this structural conservatism limits financial distress risk, enabling management to prioritize clinical readouts rather than debt servicing.
Extended RunwayLoan amendment and targeted cost reductions materially extend operating runway into Q3 2027, lowering near-term refinancing pressure. This structural extension provides time to achieve clinical/toxicology milestones or seek partnerships without immediate dilutive financings.
Focused PipelineConcentrating resources on multiple mid-stage programs preserves multiple independent value drivers. If one program succeeds, it can re-rate the company or enable partnering/licensing, making the pipeline diversification a durable source of potential value creation over the next several quarters.
Bears Say
No RevenueAs a pre-commercial biotech, absence of revenue means perpetual reliance on external financing. Persistent large losses limit internal funding capacity, increasing dependency on markets or partners; structurally raises dilution risk and constrains long-term investment flexibility.
Negative Cash FlowSustained negative operating and free cash flow that has deteriorated year-over-year creates recurring financing needs. Even with low debt, ongoing cash burn elevates dilution risk and can force prioritization or delays in clinical programs absent successful milestone-driven financings.
Late-stage Program LossDiscontinuation of a Phase 3 asset is a structural setback: it removes a near-term commercialization path and reduces tangible value catalysts. The company now relies on earlier-stage programs, increasing clinical risk and making partnering or financing more challenging long term.
Neumora Therapeutics, Inc. News
NMRA FAQ
What was Neumora Therapeutics, Inc.’s price range in the past 12 months?
Neumora Therapeutics, Inc. lowest stock price was $0.83 and its highest was $3.65 in the past 12 months.
What is Neumora Therapeutics, Inc.’s market cap?
Neumora Therapeutics, Inc.’s market cap is $294.60M.
When is Neumora Therapeutics, Inc.’s upcoming earnings report date?
Neumora Therapeutics, Inc.’s upcoming earnings report date is Aug 12, 2026 which is in 34 days.
How were Neumora Therapeutics, Inc.’s earnings last quarter?
Neumora Therapeutics, Inc. released its earnings results on May 07, 2026. The company reported -$0.3 earnings per share for the quarter, beating the consensus estimate of -$0.316 by $0.016.
Is Neumora Therapeutics, Inc. overvalued?
According to Wall Street analysts Neumora Therapeutics, Inc.’s price is currently Undervalued.
Does Neumora Therapeutics, Inc. pay dividends?
Neumora Therapeutics, Inc. does not currently pay dividends.
What is Neumora Therapeutics, Inc.’s EPS estimate?
Neumora Therapeutics, Inc.’s EPS estimate is -0.24.
How many shares outstanding does Neumora Therapeutics, Inc. have?
Neumora Therapeutics, Inc. has 185,284,240 shares outstanding.
What happened to Neumora Therapeutics, Inc.’s price movement after its last earnings report?
Neumora Therapeutics, Inc. reported an EPS of -$0.3 in its last earnings report, beating expectations of -$0.316. Following the earnings report the stock price went down -16.738%.
Which hedge fund is a major shareholder of Neumora Therapeutics, Inc.?
Currently, no hedge funds are holding shares in NMRA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Neumora Therapeutics, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.67 (210.08% Upside)
$6.67 (210.08% Upside)
Hedge Fund Trend
Increased
By 4.9M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.5%
Last 30 Days ▼ 2.7%
Last 30 Days ▼ 2.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-89.79%
12-Months-Change
Fundamentals
Return on Equity
-181.70%
Trailing 12-Months
Asset Growth
-40.07%
Trailing 12-Months
Company Description
Neumora Therapeutics, Inc.
Neumora Therapeutics, Inc. is a specialized biopharmaceutical company progressing through clinical trials, dedicated to advancing therapies for a range of neurological, psychiatric, and neurodegenerative conditions. Its most advanced candidate, navacaprant (also known as NMRA-140), is a novel, once-daily oral kappa opioid receptor antagonist currently undergoing Phase 3 clinical trials for the management of major depressive disorder. Additionally, NMRA-511 is in Phase 1 studies, targeting agitation experienced by individuals with Alzheimer's-related dementia. Another compound, NMRA-266, is also in Phase 1 clinical development, aimed at addressing schizophrenia and other related neuropsychiatric conditions. Beyond its clinical programs, Neumora maintains a preclinical pipeline featuring several promising candidates: NMRA-NMDA for schizophrenia, NMRA-CK1d (a CK1d inhibitor initiative) for amyotrophic lateral sclerosis (ALS), NMRA-NLRP3 for specific neurodegenerative ailments, and NMRA-GCase for Parkinson's disease. Tracing its origins to a 2019 incorporation, the company, initially known as RBNC Therapeutics, Inc., adopted its current name, Neumora Therapeutics, Inc., in October 2021. Its corporate headquarters are situated in Watertown, Massachusetts.
NMRA Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong scientific and clinical momentum across several programs with multiple near-term catalysts (NMRA-511, navacaprant KOASTAL-2/3, NMRA-898) and compelling preclinical/early clinical data (notably NMRA-511 effect sizes and NMRA-215 DIO results). However, a non-dose-dependent adverse signal in a 13-week rat tox study for NMRA-215, associated study conduct issues and the need to repeat toxicology introduce timeline, regulatory and cost risk for that program. Financial runway of $182.5M into Q3 2027 is adequate for the near term but will require careful capital allocation as multiple programs advance. Overall, positives on pipeline progress and enrollments outweigh the headwinds from the NMRA-215 tox delay and finite cash runway, but risks remain tied to upcoming pivotal readouts.View all NMRA earnings summariesNMRA Stock 12 Month Forecast
Average Price Target
$6.67
▲(210.08% Upside)
Technical Analysis
Abeona Therapeutics
―
AC Immune SA
―
Allogene Therapeutics
―
―
Aardvark Therapeutics, Inc.
―
Ownership Overview
59.25% Insiders
3.26% Mutual Funds
0.09% Other Institutional Investors
32.11% Public Companies and
Individual Investors